Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Günzburg WH[au]:

Search results

Items: 1 to 50 of 130

1.

Release characteristics of cellulose sulphate capsules and production of cytokines from encapsulated cells.

Salmons B, Gunzburg WH.

Int J Pharm. 2018 Sep 5;548(1):15-22. doi: 10.1016/j.ijpharm.2018.06.040. Epub 2018 Jun 19.

PMID:
29933063
2.

Commentary regarding Gannon et al. "Viral infections and breast cancer - A current perspective".

Lawson JS, Salmons B, Gunzburg WH.

Cancer Lett. 2018 Jun 28;424:117-118. doi: 10.1016/j.canlet.2018.03.028. Epub 2018 Mar 23. No abstract available.

PMID:
29580809
3.

Comment on Patel et al; "Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses" Nanomedicine, 2015. 11(5): p. 1097-107.

Metzner C, Salmons B, Günzburg WH, Dangerfield JA.

Nanomedicine. 2016 Apr;12(3):665-666. doi: 10.1016/j.nano.2015.10.013. Epub 2015 Nov 22. No abstract available.

PMID:
26593637
4.

Commentary: With a little help from my enteric microbial friends.

Gunzburg WH, Salmons B.

Front Microbiol. 2015 Sep 25;6:1029. doi: 10.3389/fmicb.2015.01029. eCollection 2015. No abstract available.

5.

Recent developments linking retroviruses to human breast cancer: infectious agent, enemy within or both?

Salmons B, Lawson JS, Günzburg WH.

J Gen Virol. 2014 Dec;95(Pt 12):2589-93. doi: 10.1099/vir.0.070631-0. Epub 2014 Sep 12. Review.

PMID:
25217613
6.

Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.

Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH.

Pharmaceutics. 2014 Aug 11;6(3):447-66. doi: 10.3390/pharmaceutics6030447. Review.

7.

Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.

Michałowska M, Winiarczyk S, Adaszek Ł, Łopuszyński W, Grądzki Z, Salmons B, Günzburg WH.

PLoS One. 2014 Jul 16;9(7):e102061. doi: 10.1371/journal.pone.0102061. eCollection 2014.

8.

Revisiting a role for a mammary tumor retrovirus in human breast cancer.

Salmons B, Gunzburg WH.

Int J Cancer. 2013 Oct 1;133(7):1530-5. doi: 10.1002/ijc.28210. Epub 2013 May 15. Review.

9.

Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.

Hlavaty J, Petznek H, Holzmüller H, Url A, Jandl G, Berger A, Salmons B, Günzburg WH, Renner M.

PLoS One. 2012;7(7):e40611. doi: 10.1371/journal.pone.0040611. Epub 2012 Jul 16.

10.

Magnetic field-controlled gene expression in encapsulated cells.

Ortner V, Kaspar C, Halter C, Töllner L, Mykhaylyk O, Walzer J, Günzburg WH, Dangerfield JA, Hohenadl C, Czerny T.

J Control Release. 2012 Mar 28;158(3):424-32. doi: 10.1016/j.jconrel.2011.12.006. Epub 2011 Dec 16.

11.

The 5' leader sequence of mouse mammary tumor virus enhances expression of the envelope and reporter genes.

Hohenadl C, Gunzburg WH, Salmons B, Indik S.

J Gen Virol. 2012 Feb;93(Pt 2):308-18. doi: 10.1099/vir.0.035196-0. Epub 2011 Nov 23.

PMID:
22113011
12.

Encapsulated cells to focus the metabolic activation of anticancer drugs.

Salmons B, Brandtner EM, Hettrich K, Wagenknecht W, Volkert B, Fischer S, Dangerfield JA, Gunzburg WH.

Curr Opin Mol Ther. 2010 Aug;12(4):450-60. Review.

PMID:
20677096
13.

Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Hlavaty J, Jandl G, Liszt M, Petznek H, König-Schuster M, Sedlak J, Egerbacher M, Weissenberger J, Salmons B, Günzburg WH, Renner M.

J Neurooncol. 2011 Mar;102(1):59-69. doi: 10.1007/s11060-010-0295-5. Epub 2010 Jul 11.

PMID:
20623247
14.

Therapeutic application of cell microencapsulation in cancer.

Salmons B, Gunzburg WH.

Adv Exp Med Biol. 2010;670:92-103. Review.

PMID:
20384221
15.

Human endogenous retroviral long terminal repeat sequences as cell type-specific promoters in retroviral vectors.

Schön U, Diem O, Leitner L, Günzburg WH, Mager DL, Salmons B, Leib-Mösch C.

J Virol. 2009 Dec;83(23):12643-50. doi: 10.1128/JVI.00858-09. Epub 2009 Sep 9.

16.

Stem cell therapies: on track but suffer setback.

Gunzburg WH, Salmons B.

Curr Opin Mol Ther. 2009 Aug;11(4):360-3. Review. No abstract available.

PMID:
19649980
17.

Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers.

Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, Stürzl M, Günzburg WH, Hohenadl C.

J Biomed Biotechnol. 2009;2009:437284. doi: 10.1155/2009/437284. Epub 2009 Mar 15.

18.

Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors.

Paar M, Klein D, Salmons B, Günzburg WH, Renner M, Portsmouth D.

BMC Mol Biol. 2009 Feb 9;10:8. doi: 10.1186/1471-2199-10-8.

19.

Singapore R&D and globetrotting.

Lear MJ, Salmons B, Gunzburg WH, Dangerfield JA.

Biotechnol J. 2009 Feb;4(2):179-85. doi: 10.1002/biot.200800131. No abstract available.

PMID:
19156748
20.

Rafts, anchors and viruses--a role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors.

Metzner C, Salmons B, Günzburg WH, Dangerfield JA.

Virology. 2008 Dec 20;382(2):125-31. doi: 10.1016/j.virol.2008.09.014. Epub 2008 Oct 28. Review.

21.

Identification of the Rem-responsive element of mouse mammary tumor virus.

Müllner M, Salmons B, Günzburg WH, Indik S.

Nucleic Acids Res. 2008 Nov;36(19):6284-94. doi: 10.1093/nar/gkn608. Epub 2008 Oct 3.

22.

Association of glycosylphosphatidylinositol-anchored protein with retroviral particles.

Metzner C, Mostegl MM, Günzburg WH, Salmons B, Dangerfield JA.

FASEB J. 2008 Aug;22(8):2734-9. doi: 10.1096/fj.08-108217. Epub 2008 May 13.

PMID:
18477763
23.

Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo.

Klein R, Ruttkowski B, Schwab S, Peterbauer T, Salmons B, Günzburg WH, Hohenadl C.

J Biomed Biotechnol. 2008;2008:683505. doi: 10.1155/2008/683505.

24.

Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.

Brandtner EM, Kodajova P, Hlavaty J, Jandl G, Tabotta W, Salmons B, Günzburg WH, Hohenadl C.

J Gene Med. 2008 Feb;10(2):113-22.

PMID:
18076132
25.

Quantification and characterization of autotransduction in retroviral vector producer cells.

Brandtner EM, Kodajova P, Knapp E, Ertl R, Tabotta W, Salmons B, Günzburg WH, Hohenadl C.

Hum Gene Ther. 2008 Jan;19(1):97-102.

PMID:
18072860
26.
27.

Mouse mammary tumor virus integration site selection in human and mouse genomes.

Faschinger A, Rouault F, Sollner J, Lukas A, Salmons B, Günzburg WH, Indik S.

J Virol. 2008 Feb;82(3):1360-7. Epub 2007 Nov 21.

28.

Rapid spread of mouse mammary tumor virus in cultured human breast cells.

Indik S, Günzburg WH, Kulich P, Salmons B, Rouault F.

Retrovirology. 2007 Oct 11;4:73.

29.

Promoter complex in the central part of the mouse mammary tumor virus long terminal repeat.

Rouault F, Nejad Asl SB, Rungaldier S, Fuchs E, Salmons B, Günzburg WH.

J Virol. 2007 Nov;81(22):12572-81. Epub 2007 Aug 8.

30.

Viruses and human breast cancer.

Lawson JS, Günzburg WH, Whitaker NJ.

Future Microbiol. 2006 Jun;1(1):33-51. Review.

PMID:
17661684
31.

Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain.

Liehl B, Hlavaty J, Moldzio R, Tonar Z, Unger H, Salmons B, Günzburg WH, Renner M.

Gene Ther. 2007 Sep;14(18):1330-43. Epub 2007 Jul 5.

PMID:
17611586
32.
33.

Bacteriophage-encoded toxins: the lambda-holin protein causes caspase-independent non-apoptotic cell death of eukaryotic cells.

Agu CA, Klein R, Lengler J, Schilcher F, Gregor W, Peterbauer T, Bläsi U, Salmons B, Günzburg WH, Hohenadl C.

Cell Microbiol. 2007 Jul;9(7):1753-65. Epub 2007 Mar 8.

PMID:
17346308
34.
35.

Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.

Lengler J, Omann M, Düvier D, Holzmüller H, Gregor W, Salmons B, Günzburg WH, Renner M.

Biochem Pharmacol. 2006 Sep 28;72(7):893-901. Epub 2006 Aug 2.

PMID:
16887103
36.

Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.

Metzl C, Mischek D, Salmons B, Günzburg WH, Renner M, Portsmouth D.

J Virol. 2006 Jul;80(14):7070-8.

37.

Enhancement of the StreptoTag method for isolation of endogenously expressed proteins with complex RNA binding targets.

Dangerfield JA, Windbichler N, Salmons B, Günzburg WH, Schröder R.

Electrophoresis. 2006 May;27(10):1874-7.

PMID:
16604572
38.

WPRE-mediated enhancement of gene expression is promoter and cell line specific.

Klein R, Ruttkowski B, Knapp E, Salmons B, Günzburg WH, Hohenadl C.

Gene. 2006 May 10;372:153-61. Epub 2006 Feb 20.

PMID:
16488559
39.

Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors.

Lipnik K, Greco O, Scott S, Knapp E, Mayrhofer E, Rosenfellner D, Günzburg WH, Salmons B, Hohenadl C.

Virology. 2006 May 25;349(1):121-33. Epub 2006 Feb 7.

40.

MMTV accessory factor Naf affects cellular gene expression.

Metzner C, Salmons B, Gunzburg WH, Gemeiner M, Miller I, Gesslbauer B, Kungl A, Dangerfield JA.

Virology. 2006 Mar 1;346(1):139-50. Epub 2005 Nov 28.

41.

Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.

Günzburg WH, Salmons B.

Acta Biochim Pol. 2005;52(3):601-7. Review.

42.

The cytotoxic activity of the bacteriophage lambda-holin protein reduces tumour growth rates in mammary cancer cell xenograft models.

Agu CA, Klein R, Schwab S, König-Schuster M, Kodajova P, Ausserlechner M, Binishofer B, Bläsi U, Salmons B, Günzburg WH, Hohenadl C.

J Gene Med. 2006 Feb;8(2):229-41.

PMID:
16170834
43.

Abundant authentic MMTV-Env production from a recombinant provirus lacking the major LTR promoter.

Rungaldier S, Nejad Asl SB, Günzburg WH, Salmons B, Rouault F.

Virology. 2005 Nov 25;342(2):201-14. Epub 2005 Sep 2.

44.

Oncolytic replicating virus therapy: is the time right?

Günzburg WH.

Curr Opin Mol Ther. 2005 Aug;7(4):291-2. No abstract available.

PMID:
16121693
45.

Mouse mammary tumor virus infects human cells.

Indik S, Günzburg WH, Salmons B, Rouault F.

Cancer Res. 2005 Aug 1;65(15):6651-9.

46.

Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors.

Hlavaty J, Schittmayer M, Stracke A, Jandl G, Knapp E, Felber BK, Salmons B, Günzburg WH, Renner M.

Virology. 2005 Oct 10;341(1):1-11.

47.

HIV-1 Rev can specifically interact with MMTV RNA and upregulate gene expression.

Dangerfield JA, Hohenadl C, Egerbacher M, Kodajova P, Salmons B, Günzburg WH.

Gene. 2005 Sep 26;358:17-30.

PMID:
16023306
48.

A 470 bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice.

Lipnik K, Petznek H, Renner-Müller I, Egerbacher M, Url A, Salmons B, Günzburg WH, Hohenadl C.

Transgenic Res. 2005 Apr;14(2):145-58.

PMID:
16022386
49.

FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein.

Lengler J, Holzmüller H, Salmons B, Günzburg WH, Renner M.

Anal Biochem. 2005 Aug 1;343(1):116-24.

PMID:
15955524
50.

A novel, mouse mammary tumor virus encoded protein with Rev-like properties.

Indik S, Günzburg WH, Salmons B, Rouault F.

Virology. 2005 Jun 20;337(1):1-6.

Supplemental Content

Loading ...
Support Center